Directed alteration of a novel bovine β-defensin to improve antimicrobial efficacy against methicillin-resistant Staphylococcus aureus (MRSA)

International Journal of Antimicrobial Agents

Volumn 32, Issue 5, 2008, Pages 392-397

  Meade, Kieran G ^a   Cahalane, Sarah ^a   Narciandi, Fernando ^a   Cormican, Paul ^a   Lloyd, Andrew T ^a   O'Farrelly, Cliona ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antimicrobial peptides; Defensin; MRSA

Indexed keywords

BETA DEFENSIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERICIDAL ACTIVITY; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SPECIFICITY; DRUG SYNTHESIS; HYDROPHILICITY; HYDROPHOBICITY; LD 50; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; SALMONELLA ENTERICA;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-DEFENSINS; CATTLE; COMPUTATIONAL BIOLOGY; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53249137787     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.05.005     Document Type: Article

References (40)

1. World Health Organization. Antibiotic resistance: synthesis of recommendations by expert policy groups (2001), WHO, Geneva, Switzerland
2. Boyce J.M., Cookson B., Christiansen K., Hori S., Vuopio-Varkila J., Kocagoz S., et al. Methicillin-resistant Staphylococcus aureus. Lancet Infect Dis 5 (2005) 653-663
3. Lee J.H. Methicillin (oxacillin)-resistant Staphylococcus aureus strains isolated from major food animals and their potential transmission to humans. Appl Environ Microbiol 69 (2003) 6489-6494
4. Girardin S.E., Sansonetti P.J., and Philpott D.J. Intracellular vs extracellular recognition of pathogens-common concepts in mammals and flies. Trends Microbiol 10 (2002) 193-199
5. Yeaman M.R., and Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev 55 (2003) 27-55
6. Niyonsaba F., Ogawa H., and Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 111 (2004) 273-281
7. Yang D., Chertov O., Bykovskaia S.N., Chen Q., Buffo M.J., Shogan J., et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286 (1999) 525-528
8. Cormican P., Meade K.G., Cahalane S., Narciandi F., Chapwanya A., Lloyd A.T., et al. Evolution, expression and effectiveness in a cluster of novel bovine beta-defensins. Immunogenetics 60 (2008) 147-156
9. Higgs R., Lynn D.J., Gaines S., McMahon J., Tierney J., James T., et al. The synthetic form of a novel chicken beta-defensin identified in silico is predominantly active against intestinal pathogens. Immunogenetics 57 (2005) 90-98
10. Lynn D.J., Higgs R., Gaines S., Tierney J., James T., Lloyd A.T., et al. Bioinformatic discovery and initial characterisation of nine novel antimicrobial peptide genes in the chicken. Immunogenetics 56 (2004) 170-177
11. Higgs R., Lynn D.J., and Cahalane S. Modification of chicken avian beta-defensin-8 at positively selected amino acid sites enhances specific antimicrobial activity. Immunogenetics 59 (2007) 573-580
12. Joerger R.D. Alternatives to antibiotics: bacteriocins, antimicrobial peptides and bacteriophages. Poult Sci 82 (2003) 640-647
13. Rothstein D.M., Helmerhorst E.J., Spacciapoli P., Oppenheim F.G., and Friden P. Histatin-derived peptides: potential agents to treat localised infections. Expert Opin Emerg Drugs 7 (2002) 47-59
14. Friedrich C.L., Rozek A., Patrzykat A., and Hancock R.E. Structure and mechanism of action of an indolicidin peptide derivative with improved activity against gram-positive bacteria. J Biol Chem 276 (2001) 24015-24022
15. Ge Y., MacDonald D., Henry M.M., Hait H.I., Nelson K.A., Lipsky B.A., et al. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers. Diagn Microbiol Infect Dis 35 (1999) 45-53
16. Andres E., and Dimarcq J.L. Cationic antimicrobial peptides: update of clinical development. J Intern Med 255 (2004) 519-520
17. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat Rev Microbiol 3 (2005) 238-250
18. Kluver E., Schulz-Maronde S., Scheid S., Meyer B., Forssmann W.G., and Adermann K. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 44 (2005) 9804-9816
19. Motizuki M., Itoh T., Satoh T., Yokota S., Yamada M., Shimamura S., et al. Lipid-binding and antimicrobial properties of synthetic peptides of bovine apolipoprotein A-II. Biochem J 342 (1999) 215-221
20. Xiao Y., Dai H., Bommineni Y.R., Soulages J.L., Gong Y.X., Prakash O., et al. Structure-activity relationships of fowlicidin-1, a cathelicidin antimicrobial peptide in chicken. FEBS J 273 (2006) 2581-2593
21. Tennessen J.A. Molecular evolution of animal antimicrobial peptides: widespread moderate positive selection. J Evol Biol 18 (2005) 1387-1394
22. Goldammer T., Zerbe H., Molenaar A., Schuberth H.J., Brunner R.M., Kata S.R., et al. Mastitis increases mammary mRNA abundance of beta-defensin 5, toll-like-receptor 2 (TLR2), and TLR4 but not TLR9 in cattle. Clin Diagn Lab Immunol 11 (2004) 174-185
23. Swanson K., Gorodetsky S., Good L., Davis S., Musgrave D., Stelwagen K., et al. Expression of a beta-defensin mRNA, lingual antimicrobial peptide, in bovine mammary epithelial tissue is induced by mastitis. Infect Immun 72 (2004) 7311-7314
24. Sahl H.G. Optimizing antimicrobial host defense peptides. Chem Biol 13 (2006) 1015-1017
25. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
26. Elsbach P. What is the real role of antimicrobial polypeptides that can mediate several other inflammatory responses?. J Clin Invest 111 (2003) 1643-1645
27. Hancock R.E., and Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24 (2006) 1551-1557
28. Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci 13 (1997) 555-556
29. Lynn D.J., Higgs R., Lloyd A.T., O'Farrelly C., Herve-Grepinet V., Nys Y., et al. Avian beta-defensin nomenclature: a community proposed update. Immunol Lett 110 (2007) 86-89
30. Garcia J.R., Jaumann F., Schulz S., Krause A., Rodriguez-Jimenez J., Forssmann U., et al. Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 306 (2001) 257-264
31. Harder J., Bartels J., Christophers E., and Schroder J.M. Isolation and characterization of human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 276 (2001) 5707-5713
32. Hopp T.P., and Woods K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 78 (1981) 3824-3828
33. Hoover D.M., Wu Z., Tucker K., Lu W., and Lubkowski J. Antimicrobial characterization of human beta-defensin 3 derivatives. Antimicrob Agents Chemother 47 (2003) 2804-2809
34. Mandal M., Jagannadham M.V., and Nagaraj R. Antibacterial activities and conformations of bovine beta-defensin BNBD-12 and analogs: structural and disulfide bridge requirements for activity. Peptides 23 (2002) 413-418
35. Wu Z., Hoover D.M., Yang D., Boulegue C., Santamaria F., Oppenheim J.J., et al. Engineering disulfide bridges to dissect antimicrobial and chemotactic activities of human beta-defensin 3. Proc Natl Acad Sci U S A 100 (2003) 8880-8885
36. Bessalle R., Haas H., Goria A., Shalit I., and Fridkin M. Augmentation of the antibacterial activity of magainin by positive-charge chain extension. Antimicrob Agents Chemother 36 (1992) 313-317
37. Matsuzaki K., Sugishita K., Harada M., Fujii N., and Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta 1327 (1997) 119-130
38. De Smet K., and Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 27 (2005) 1337-1347
39. Motzkus D., Schulz-Maronde S., Heitland A., Schulz A., Forssmann W.G., Jubner M., et al. The novel beta-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J 20 (2006) 1701-1702
40. Deslouches B., Phadke S.M., Lazarevic V., Cascio M., Islam K., Montelaro R.C., et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother 49 (2005) 316-322